Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report.
Miller
David E
DE
Sebastian
C Simon
CS
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D001971:Bromocriptine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005687:Galactorrhea / Q000139:chemically induced* / Q000188:drug therapy* / Q000517:prevention & control; D006727:Hormone Antagonists / Q000627:therapeutic use*; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced* / Q000188:drug therapy* / Q000517:prevention & control; D000077152:Olanzapine; D011388:Prolactin / Q000097:blood; D011618:Psychotic Disorders / Q000097:blood / Q000188:drug therapy
D014150:Antipsychotic Agents; D006727:Hormone Antagonists; D001569:Benzodiazepines; D001971:Bromocriptine; D011388:Prolactin; D000077152:Olanzapine